Protamine (most commonly used as protamine sulfate) is a small, strongly alkaline protein traditionally derived from fish (such as salmon sperm) or produced via recombinant methods.
Originally isolated from salmon sperm: pharmaceutical preparations are now often recombinant.
It is rich in arginine residues, giving it a high positive charge. It is administered intravenously as a sterile solution (typically 10 mg/mL).
Protamine sulfate is a strongly basic (polycationic) protein used primarily as the specific antagonist to reverse the anticoagulant effects of unfractionated heparin (UFH).
It acts as a specific reversal agent for the anticoagulant heparin.
Heparin Reversal: It neutralizes the anticoagulant effect of unfractionated heparin (UFH), typically administered after heart surgery (such as cardiopulmonary bypass), vascular surgery, or to treat heparin overdose.
Low-Molecular-Weight Heparin (LMWH): It provides partial reversal for LMWHs like enoxaparin, though its effectiveness is less complete because it does not bind as strongly to shorter heparin chains.
Other Uses: It also serves as a slow-release component in certain intermediate-acting insulin formulations (such as NPH insulin) and is explored in molecular delivery systems.
Protamine is a positively charged (cationic) protein that binds to negatively charged (anionic) heparin molecules.
This electrostatic binding forms a stable, inactive salt aggregate, rapidly neutralizing heparin’s blood-thinning properties within about 5 minutes of intravenous injection.
The complex has a relatively short half-life (~10 minutes for free protamine).
Protamine binds electrostatically to the strongly anionic heparin molecule, forming a stable inactive salt complex that has no anticoagulant activity.
If given in significant excess without heparin present, protamine itself can act as a weak anticoagulant.
Administration and Dosing
Administered strictly via slow intravenous (IV) injection or infusion and is often guided by coagulation tests like ACT or aPTT).
Dosing (Unfractionated Heparin): Commonly calculated as roughly 1 to 1.5 mg of protamine per 100 units of heparin, adjusted downward depending on how much time has elapsed since the heparin was last given.
Side Effects and Risks:
Cardiovascular: Rapid injection can trigger severe hypotension, bradycardia and flushing-histamine-mediated Type 1 reaction).
Allergic Reactions: Anaphylactoid or severe allergic/anaphylactic reactions can occur, with a higher risk observed in patients with fish allergies, prior vasectomy, or exposure to protamine-containing insulins.
Pulmonary: Can occasionally cause pulmonary vasoconstriction or pulmonary hypertension in specific reaction types.
It incompletely neutralizes low-molecular-weight heparins (LMWHs) because it does not fully bind the smaller fragments responsible for anti-factor Xa activity; anti-IIa activity is more completely reversed than anti-Xa activity.
When given alone in the absence of heparin, protamine itself has weak anticoagulant properties through effects on platelets, fibrinogen, and thromboplastin generation.
Clinical Uses
Primary approved indication: Treatment of heparin overdosage and neutralization of UFH anticoagulation.
Reversal after cardiopulmonary bypass / cardiac surgery to restore hemostasis and reduce postoperative bleeding.
Reversal during or after dialysis, invasive vascular procedures, or in selected cases of acute ischemic stroke when UFH was used.
Partial/off-label use for LMWH overdosage:guidelines sometimes recommend it, but evidence quality is low and neutralization is incomplete.
Combined with insulin (e.g., neutral protamine Hagedorn / NPH insulin) to delay absorption and prolong duration of action.
Typical starting ratio is approximately 1 mg protamine per 100 units of residual UFH, adjusted for the amount of heparin given and time elapsed since the last dose as heparin half-life is short.
Administer by slow IV injection (generally not exceeding 50 mg over 10 minutes) to reduce the risk of severe reactions.
Overdosing can paradoxically increase bleeding risk due to protamine’s intrinsic anticoagulant effects.
Point-of-care heparin assays or activated clotting time (ACT) guidance is often used in cardiac surgery.
Common or notable reactions include: Hypotension, bradycardia, flushing/warmth Anaphylactic or anaphylactoid reactions (systemic hypotension, pulmonary vasoconstriction/hypertension, bronchoconstriction) Noncardiogenic pulmonary edema Nausea, vomiting, back pain
Risk factors for severe reactions include rapid administration, high or repeated doses, prior exposure to protamine or protamine-containing products (NPH insulin, certain other formulations), fish allergy, prior vasectomy, and severe left-ventricular dysfunction or abnormal pulmonary hemodynamics.
Hyperheparinemia/heparin rebound can occasionally occur hours after apparent complete neutralization, particularly after cardiopulmonary bypass.
Contraindication: Known prior intolerance/hypersensitivity to protamine.
Protamine remains the only widely available specific clinical agent for rapid UFH reversal.